

111. (New) A kit of claim 98, wherein said CDRs of said anti-mesothelin antibody have the sequence of the CDRs of SEQ ID NO:5.

112. (New) A kit of claim 111, wherein said antibody is a scFv.

REMARKS

Applicants hereby respond to the Restriction Requirement dated October 11, 2001. Applicants traverse the restriction and maintain that all the claims should be examined by the Examiner in this proceeding.

Applicants further amend claim 97 and add new claims 99-112.

No new matter has been added by the amendments or by the new claims. The amendment to claims 97 and 98 incorporate the recitation of claim 20 into the claims to recast them as independent claims and introduce the term "complementarity-determining regions" (or "CDRs") into the claims to provide antecedence for that term in the new claims. CDRs are discussed throughout the specification, including page 9, lines 3-14. The amendment to claim 97 also conforms the claim to the format currently preferred by the Office for compositions comprising pharmaceutically acceptable carriers

The new claims are supported throughout the specification.

Pharmaceutical compositions of the antibodies and immunoconjugates of the invention are supported at, among other places, page 33, line 26, to page 36, line 13. New claims 99-102 are specifically supported by these pages and by page 17, line 18 through page 18, line 5. New claims 103-105 are supported by pages 33-36 and parallel and are specifically supported by original claims 23-25. New claim 106 is supported by pages 33-36 and by original claim 16. New claims 107 and 108 are supported by pages 33-36 and by original claims 11 and 12.

Kits comprising antibodies and immunoconjugates of the invention are supported at, among other places, page 36, line 15 to page 37, line 14. New claims 109-112 are supported by these pages and by page 17, line 18 through page 18, line 5.



COPY OF PAPERS
ORIGINALLY FILED

PATENT

RECEIVED

MAR - 8 2002

TECH CENTER 1600/2900

MARKED UP VERSION TO SHOW CHANGES

IN THE CLAIMS

Please **amend** claims 97 and 98 as follows:

97. (Amended) A [pharmaceutical] composition comprising [the immunoconjugate of claim 20] a pharmaceutically acceptable carrier and a recombinant immunoconjugate which comprises a therapeutic agent or a detectable label bonded to an anti-mesothelin antibody having complementarity-determining regions ("CDRs"), which antibody binds to recombinant mesothelin with a dissociation constant of less than 3×10^{-8} M and which specifically binds to cells expressing mesothelin on their cell surface.

98. (Amended) A kit for detecting mesothelin on the surface of cells, said kit comprising:

(i) an anti-mesothelin antibody [which binds to recombinant mesothelin with a] having complementarity-determining regions ("CDRs"), which antibody binds to recombinant mesothelin with a dissociation constant of less than 3×10^{-8} M and which specifically binds to cells expressing mesothelin on their cell surface; and

(ii) instructions printed on a tangible medium, said instructions describing the methods of using and uses for said antibody.